The Patent Finder

Terms ending in 2037

Immunocore Limited

Every in-force patent on Immunocore Limited's record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,739,442TCR Libraries
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 11,739,441TCR Libraries
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 10,835,577Peptides Derived from Kita-Kyushu Lung Cancer Antigen (KKLC1, CT83, CXORF61) and Complexes Comprising Such Peptides Bound to MHC Molecules
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
US 12,698,316Engineered Immune-Mobilizing T-Cell Receptors with Enhanced Affinity for HIV-1 Gag
In force
 · Medium confidence
Immunocore LimitedIn forceMedium confidence
US 10,851,366Peptides Derived from Lengsin (LGSN), Complexes Comprising Such Peptides Bound to MHC Molecules
In force
 · High confidence
Immunocore LimitedIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited